Biotech IV Monitor

GKOS — Glaukos Corporation

$9.0B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Glaukos Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.

Next readoutApril 2027in ~5 months
Upcoming readouts31 Phase 3
Market cap$9.0B
Cash & investments$337Mas of Sep 30, 2026
Recent 8-K filings2latest 2026-11-06

Upcoming readouts

Phase 2 GLK-221 Ophthalmic Solution
Keratoconus · NCT07400952
April 2027
Recruiting
Phase 2 Gen 2 Travoprost Intracameral Implant
Glaucoma · NCT07075718
March 2028
Recruiting
Phase 3 Gen 2 Travoprost Intracameral Implant
Glaucoma · NCT07495852
June 2028
Recruiting

Cash position

Glaukos Corporation reported $337M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-28). It reported net income of $2M for that quarter.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-06
8-K Reg FD Disclosure — often a data announcement2026-10-28

Discussion

No messages yet. If you follow GKOS, you can start the conversation.
Track GKOS in real time
See live implied volatility for GKOS and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on GKOS
Contact — questions or corrections about GKOS: dukeupt@gmail.com